A--Drug Manufacturing and Formulation Program (DMFP)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
Four indefinite-delivery/indefinite-quantity contracts have been awarded under the Drug Manufacturing and Formulation Program with a combined maximum ordering value of $49,999,999.00 each, spanning a ten-year period from May 4, 2026, to May 3, 2036. Each contract was issued simultaneously with an initial task order effective May 4, 2026, through July 3, 2026, at a firm-fixed price of $5,000.00 per awardee. The procurement was conducted by the National Institutes of Health, National Institute on Drug Abuse, under solicitation number 75N95024R00077, and falls under NAICS code 325412 for pharmaceutical and medicine manufacturing. No small business set-aside was applied. The contracting office is located in Bethesda, Maryland, while the primary place of performance is in Kansas City, Missouri. Primary point of contact is Rieka N. Plugge, with Kelly Dempsey serving as secondary contact for inquiries.
General Info
Agency
Contract Value
$49,999,999NAICS
Place of Performance
Kansas City, MO, USASet-Aside
Awardee
Award Issued Date
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
